Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3
After a Phase 2 interim analysis showed insufficient efficacy, the company is dropping two prostate cancer candidates and refocusing on roxadustat in lower-risk myelodysplastic syndromes, subject to funding.
Kyntra Bio, Inc. has stopped development of FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer. The company announced the decision with its third-quarter 2026 results on 16 November 2026, saying the Phase 2 interim analysis showed insufficient efficacy.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Kyntra Bio, Inc. ↗
Article written by VigiEye from the official source (Kyntra Bio, Inc.). Claims are the company's own. AI-assisted; check the source before acting.